Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F de Braud

Showing results (31-40 of 140) with videos related to

Pageof 14
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 26, 2013
Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapseS Di Cosimo, D Serpico, L Porcu, et al.
The Journal of Vascular Access|July 20, 2007
Ultrasound guided versus direct vein puncture in central venous port placementF Orsi, R F Grasso, P Arnaldi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 24, 2001
Very low acute toxicity of three fractions per day accelerated radiotherapy given after induction chemotherapy and surgery in stage III non-small cell lung cancerT de Pas, G Catalano, U Pastorino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2000
Friedreich's ataxia and intrathecal chemotherapy in a patient with lymphoblastic lymphomaT De Pas, G Martinelli, F De Braud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancerS Fogli, R Danesi, F De Braud, et al.
Critical Reviews in Oncology/Hematology|December 21, 2013
Targeting the MET gene for the treatment of non-small-cell lung cancerF Gelsomino, F Facchinetti, E R Haspinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 daysR Biffi, F de Braud, F Orsi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 20, 2009
Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administrationT M De Pas, F Toffalorio, C Catania, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1993
Effective salvage chemotherapy in relapsed or refractory non-Hodgkin's lymphomaR Buzzoni, M Colleoni, E Bajetta, et al.
Biopharmaceutics & Drug Disposition|December 18, 2001
Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patientsC U Pfister, A Martoni, C Zamagni, et al.
Pageof 14

Showing results (31-40 of 140) with videos related to

Sort By:
Pageof 14
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 26, 2013
Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapseS Di Cosimo, D Serpico, L Porcu, et al.
The Journal of Vascular Access|July 20, 2007
Ultrasound guided versus direct vein puncture in central venous port placementF Orsi, R F Grasso, P Arnaldi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 24, 2001
Very low acute toxicity of three fractions per day accelerated radiotherapy given after induction chemotherapy and surgery in stage III non-small cell lung cancerT de Pas, G Catalano, U Pastorino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2000
Friedreich's ataxia and intrathecal chemotherapy in a patient with lymphoblastic lymphomaT De Pas, G Martinelli, F De Braud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancerS Fogli, R Danesi, F De Braud, et al.
Critical Reviews in Oncology/Hematology|December 21, 2013
Targeting the MET gene for the treatment of non-small-cell lung cancerF Gelsomino, F Facchinetti, E R Haspinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 daysR Biffi, F de Braud, F Orsi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 20, 2009
Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administrationT M De Pas, F Toffalorio, C Catania, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1993
Effective salvage chemotherapy in relapsed or refractory non-Hodgkin's lymphomaR Buzzoni, M Colleoni, E Bajetta, et al.
Biopharmaceutics & Drug Disposition|December 18, 2001
Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patientsC U Pfister, A Martoni, C Zamagni, et al.
Pageof 14